1. Cromolyn Eye Drops recalled in Canada due to risk of infections

   News item 12 August 2023 Pages: 1 - 1

2. FDA approves RiVive naloxone nasal spray for opioid overdose

   News item 12 August 2023 Pages: 2 - 2

3. FDA warns that two lots of Tydemy may have lower efficacy

   News item 12 August 2023 Pages: 3 - 3

4. No association between mRNA COVID-19 vaccines and menorrhagia

   News item 12 August 2023 Pages: 4 - 4

5. Assessing ADR reports for recently approved antidiabetic medications

   Epidemiology population study 12 August 2023 Pages: 5 - 5

6. BCR-ABL TKI fluid retention-related AEs

   Clinical study 12 August 2023 Pages: 6 - 6

7. Bisphosphonate-related risk of skin ulcers?

   Epidemiology population study 12 August 2023 Pages: 7 - 7

8. Cannabidiol- and tetrahydrocannabinol-related AEs

   Clinical study 12 August 2023 Pages: 8 - 8

9. Guidance on acceptable levels of NDSRI nitrosamine impurities

   News item 12 August 2023 Pages: 9 - 9

10. Immune checkpoint inhibitor-related chronic irAEs

    Clinical study 12 August 2023 Pages: 10 - 10

11. Lasmiditan-related neurological and psychiatric disorders

    Epidemiology population study 12 August 2023 Pages: 11 - 11

12. Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD

    Clinical study 12 August 2023 Pages: 12 - 12

13. Other adverse reaction research

    News item 12 August 2023 Pages: 13 - 13

14. ​Multiple drugs

    Case report 12 August 2023 Pages: 14 - 14

15. Abatacept/adalimumab

    Case report 12 August 2023 Pages: 15 - 15

16. Abemaciclib

    Case report 12 August 2023 Pages: 16 - 16

17. Acamprosate/chlordiazepoxide

    Case report 12 August 2023 Pages: 17 - 17

18. Acetazolamide

    Case report 12 August 2023 Pages: 18 - 18

19. Acetylcysteine

    Case report 12 August 2023 Pages: 19 - 19

20. Ad26.cov2-s/prednisone

    Case report 12 August 2023 Pages: 20 - 20

21. Adalimumab

    Case report 12 August 2023 Pages: 21 - 21

22. Adalimumab/ciclosporin

    Case report 12 August 2023 Pages: 22 - 22

23. Adalimumab/leflunomide/levofloxacin

    Case report 12 August 2023 Pages: 23 - 23

24. Adalimumab/methotrexate

    Case report 12 August 2023 Pages: 24 - 24

25. Adalimumab/vedolizumab

    Case report 12 August 2023 Pages: 25 - 25

26. Aflibercept/ranibizumab/triamcinolone

    Case report 12 August 2023 Pages: 26 - 26

27. Alcohol

    Case report 12 August 2023 Pages: 27 - 27

28. Amfetamine

    Case report 12 August 2023 Pages: 28 - 28

29. Amiodarone

    Case report 12 August 2023 Pages: 29 - 29

30. Amiodarone/metoprolol

    Case report 12 August 2023 Pages: 30 - 30

31. Amoxicillin

    Case report 12 August 2023 Pages: 31 - 31

32. Amphotericin B liposomal

    Case report 12 August 2023 Pages: 32 - 32

33. Ampicillin/sulbactam

    Case report 12 August 2023 Pages: 33 - 33

34. Anakinra/ciclosporin/corticosteroids

    Case report 12 August 2023 Pages: 34 - 34

35. Anti-inflammatories/azathioprine

    Case report 12 August 2023 Pages: 35 - 35

36. Anti-inflammatories/bromocriptine/ceftriaxone

    Case report 12 August 2023 Pages: 36 - 36

37. Antibacterials/antifungals/antituberculars

    Case report 12 August 2023 Pages: 37 - 37

38. Antibacterials/dexamethasone

    Case report 12 August 2023 Pages: 38 - 38

39. Anticoagulants

    Case report 12 August 2023 Pages: 39 - 39

40. Anticoagulants/carbasalate-calcium

    Case report 12 August 2023 Pages: 40 - 40

41. Antiepileptic-drugs

    Case report 12 August 2023 Pages: 41 - 41

42. Antineoplastics

    Case report 12 August 2023 Pages: 42 - 42

43. Antineoplastics

    Case report 12 August 2023 Pages: 43 - 43

44. Antineoplastics

    Case report 12 August 2023 Pages: 44 - 44

45. Antineoplastics

    Case report 12 August 2023 Pages: 45 - 46

46. Antineoplastics

    Case report 12 August 2023 Pages: 46 - 46

47. Antineoplastics/mefloquine/tacrolimus

    Case report 12 August 2023 Pages: 47 - 47

48. Antithyroids/lithium/propranolol

    Case report 12 August 2023 Pages: 48 - 48

49. Antituberculars

    Case report 12 August 2023 Pages: 49 - 49

50. Antituberculars/nintedanib

    Case report 12 August 2023 Pages: 50 - 50